(+)-Matrine - CAS 519-02-8
Not Intended for Therapeutic Use. For research use only.
Category:
Inhibitor
Product Name:
(+)-Matrine
Catalog Number:
519-02-8
CAS Number:
519-02-8
Description:
Matrine((+)-Matrine) is an alkaloid found in plants from the Sophora family, which has a variety of pharmacological effects, including anti-cancer effects, and action as a kappa opioid receptor agonist.
Molecular Weight:
248.36
Molecular Formula:
C15H24N2O
COA:
Inquire
MSDS:
Inquire
Targets:
Opioid Receptor
Chemical Structure
CAS 519-02-8 (+)-Matrine

Related Opioid Receptor Products


LY2795050
(CAS: 1346133-08-1)

LY2795050, a κ-opioid Receptor antagonist, has been found to be effective in imaging KOR behaving as a PET tracer. IC50: 0.72 nM and 25.8 nM for κ-opioid Recept...

PZM-21
(CAS: 1997387-43-5)

PZM-21 is a potent Gi activator which has selectivity for μOR. It is an experimental opioid analgesic drug promisingly used for the treatment of pain. Study ind...

GSK1521498
(CAS: 1007573-18-3)

GSK-1521498 is a novel μ-Opioid receptor antagonist. It shows to attenuate reward-driven compulsive behaviours, such as stimulant drug seeking or binge eating i...

CAS 1401031-39-7 TRV130 HCl

TRV130 HCl
(CAS: 1401031-39-7)

TRV130 is an opioid drug that is under evaluation in human clinical trials for the treatment of acute severe pain. It is a functionally selective μ-opioid recep...

CAS 1108147-88-1 MCOPPB triHydrochloride

MCOPPB triHydrochloride
(CAS: 1108147-88-1)

The trihydrochloride salt form of MCOPPB, an effective full agonist of nociceptin receptor, could be a good antianxiety agent with few side-effects. pKi: 10.07.

CAS 244218-51-7 JTC-801

JTC-801
(CAS: 244218-51-7)

JTC-801 is a selective opioid receptor-like1 (ORL1) receptor antagonist with IC50 of 94 nM, weakly inhibits receptors δ, κ, and μ. It is an opioid analgesic dru...

CAS 519-02-8 (+)-Matrine

(+)-Matrine
(CAS: 519-02-8)

Matrine((+)-Matrine) is an alkaloid found in plants from the Sophora family, which has a variety of pharmacological effects, including anti-cancer effects, and ...

CAS 152657-84-6 Nalfurafine

Nalfurafine
(CAS: 152657-84-6)

Nalfurafine is a selective and centrally-penetrant κ-opioid receptor (KOR) agonist without significant activity on μ- and δ-opioid receptors. With antipruritic ...

Naloxegol
(CAS: 854601-70-0)

Naloxegol is a CYP3A4 enzyme inhibitor. It is also a peripherally-selective opioid antagonist. It is used as the treatment of opioid-induced constipation. lt is...

CAS 357-08-4 Naloxone hydrochloride

Naloxone hydrochloride
(CAS: 357-08-4)

Naloxone HCl is an opioid inverse agonist drug used to counter the effects of opiate overdose.

CAS 58569-55-4 Met-Enkephalin

Met-Enkephalin
(CAS: 58569-55-4)

Met-Enkephalin is synthetic opioid peptides that has opioid effects of a relatively short duration.

CAS 34552-83-5 Loperamide HCl

Loperamide HCl
(CAS: 34552-83-5)

Loperamide HCl is an opioid-receptor agonist with an ED50 of 0.15 mg/kg.

PD-117302
(CAS: 111728-01-9)

PD-117302, a new nonpeptide opioid compound, is a selective kappa-opioid agonist. It has been evaluated in vivo for antinociceptive activity and other effects c...

CAS 39133-31-8 Trimebutine

Trimebutine
(CAS: 39133-31-8)

Trimebutine is an agonist of peripheral mu, kappa and delta opiate receptors, used as spasmolytic agent for treatment of both acute and chronic abdominal pain.

(+)-Igmesine hydrochloride
(CAS: 130152-35-1)

Igmesine is a selective σ1 receptor ligand (KD = 19.1 nM), with nearly no activity at σ2 receptors (IC50 > 1000 nM). It was developed by Pfizer. Igmesine inhibi...

CP866087
(CAS: 519052-02-9)

CP866087 is a selective mu-opioid receptor antagonist.

CAS 850173-95-4 ADL5859 HCl

ADL5859 HCl
(CAS: 850173-95-4)

ADL5859 HCl is a δ-opioid receptor agonist with Ki of 0.8 nM, selectivity against opioid receptor κ, μ, and weak inhibitory activity at the hERG channel.

CAS 20410-95-1 6 α-naloxol

6 α-naloxol
(CAS: 20410-95-1)

6 α-naloxol, a human metabolite of naloxone, is an opioid antagonist.

CAS 58-74-2 Papaverine

Papaverine
(CAS: 58-74-2)

Papaverine is an opiate alkaloid isolated from the plant Papaver somniferum. It is used primarily in the treatment of visceral spasm, vasospasm. It is also used...

Difelikefalin
(CAS: 1024828-77-0)

Difelikefalin is an analgesic opioid peptide acting as a peripherally specific, highly selective agonist of the κ-opioid receptor (KOR). It acts as an analgesic...

Reference Reading


1.Antiparasitic effects of oxymatrine and matrine against Toxoplasma gondii in vitro and in vivo.
Zhang X1, Jin L1, Cui Z2, Zhang C1, Wu X3, Park H4, Quan H5, Jin C6. Exp Parasitol. 2016 Mar 16;165:95-102. doi: 10.1016/j.exppara.2016.03.020. [Epub ahead of print]
Toxoplasma gondii (T. gondii) is an important pathogen which can causes serious public health problems. Since the current therapeutic drugs for toxoplasmosis present serious host toxicity, research on effective and new substances of relatively low toxicity is urgently needed. This study was carried out to evaluate the anti-parasitic effect of oxymatrine (OM) and matrine (ME) against T. gondii in vitro and in vivo. In our study, the anti-T. gondii activities of ME and OM were evaluated in vitro using cell counting kit-8 assay, morphological observation and trypan blue exclusion assay. In vivo, mice were sacrificed four days post-infection and ascites were drawn out to determine the extent of tachyzoite proliferation. Viscera indexes and liver biochemical parameters, such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), glutathione (GSH) and malondialdehyde (MDA), were examined to evaluate the toxicity of compounds to mice.
2.A Novel, Multi-Target Natural Drug Candidate, Matrine, Improves Cognitive Deficits in Alzheimer's Disease Transgenic Mice by Inhibiting Aβ Aggregation and Blocking the RAGE/Aβ Axis.
Cui L1, Cai Y2, Cheng W2, Liu G2, Zhao J2,3, Cao H4, Tao H2,3, Wang Y5, Yin M2, Liu T2, Liu Y2, Huang P2, Liu Z2, Li K1,6, Zhao B7. Mol Neurobiol. 2016 Feb 22. [Epub ahead of print]
The treatment of AD is a topic that has puzzled researchers for many years. Current mainstream theories still consider Aβ to be the most important target for the cure of AD. In this study, we attempted to explore multiple targets for AD treatments with the aim of identifying a qualified compound that could both inhibit the aggregation of Aβ and block the RAGE/Aβ axis. We believed that a compound that targets both Aβ and RAGE may be a feasible strategy for AD treatment. A novel and small natural compound, Matrine (Mat), was identified by high-throughput screening of the main components of traditional Chinese herbs used to treat dementia. Various experimental techniques were used to evaluate the effect of Mat on these two targets both in vitro and in AD mouse model. Mat could inhibit Aβ42-induced cytotoxicity and suppress the Aβ/RAGE signaling pathway in vitro. Additionally, the results of in vivo evaluations of the effects of Mat on the two targets were consistent with the results of our in vitro studies.
3.A Novel, Multi-Target Natural Drug Candidate, Matrine, Improves Cognitive Deficits in Alzheimer's Disease Transgenic Mice by Inhibiting Aβ Aggregation and Blocking the RAGE/Aβ Axis.
Cui L1, Cai Y2, Cheng W2, Liu G2, Zhao J2,3, Cao H4, Tao H2,3, Wang Y5, Yin M2, Liu T2, Liu Y2, Huang P2, Liu Z2, Li K1,6, Zhao B7. Mol Neurobiol. 2016 Feb 22. [Epub ahead of print]
The treatment of AD is a topic that has puzzled researchers for many years. Current mainstream theories still consider Aβ to be the most important target for the cure of AD. In this study, we attempted to explore multiple targets for AD treatments with the aim of identifying a qualified compound that could both inhibit the aggregation of Aβ and block the RAGE/Aβ axis. We believed that a compound that targets both Aβ and RAGE may be a feasible strategy for AD treatment. A novel and small natural compound, Matrine (Mat), was identified by high-throughput screening of the main components of traditional Chinese herbs used to treat dementia. Various experimental techniques were used to evaluate the effect of Mat on these two targets both in vitro and in AD mouse model. Mat could inhibit Aβ42-induced cytotoxicity and suppress the Aβ/RAGE signaling pathway in vitro. Additionally, the results of in vivo evaluations of the effects of Mat on the two targets were consistent with the results of our in vitro studies.